These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38712353)

  • 1. The association between BMI and continuity of etonogestrel (ENG)-releasing implant.
    Mohr-Sasson A; Dalal L; Bhalwal A
    Int J Gynaecol Obstet; 2024 Oct; 167(1):254-258. PubMed ID: 38712353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding.
    Ireland LD; Goyal V; Raker CA; Murray A; Allen RH
    Contraception; 2014 Sep; 90(3):253-8. PubMed ID: 24973904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
    Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
    Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of etonogestrel subcutaneous implant in Sardinia, Italy: women's compliance and satisfaction.
    Capobianco G; Sanna E; Gulotta A; Virdis G; Dessole F; Maida I; Madonia M; Cudoni F; Petrillo M
    Eur J Contracept Reprod Health Care; 2024 Aug; 29(4):171-176. PubMed ID: 38785129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immediate postpartum etonogestrel implant: a contraception option with long-term continuation.
    Wilson S; Tennant C; Sammel MD; Schreiber C
    Contraception; 2014 Sep; 90(3):259-64. PubMed ID: 24993485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menstrual bleeding patterns in adolescents using etonogestrel (ENG) implant.
    Deokar AM; Jackson W; Omar HA
    Int J Adolesc Med Health; 2011; 23(1):75-7. PubMed ID: 21721368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial.
    Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM
    Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
    Bahamondes L; Brache V; Ali M; Habib N;
    Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing Weight Status in Adolescent and Young Adult Users of the Etonogestrel Contraceptive Implant.
    Romano ME; Braun-Courville DK
    J Pediatr Adolesc Gynecol; 2019 Aug; 32(4):409-414. PubMed ID: 30928532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of early discontinuation and associated factors among a retrospective cohort of etonogestrel contraceptive implant users.
    Peterson AM; Brown A; Savage A; Dempsey A
    Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):475-479. PubMed ID: 31545110
    [No Abstract]   [Full Text] [Related]  

  • 15. Twelve-month Continuation of the Etonogestrel Implant in Adolescents With Polycystic Ovary Syndrome.
    Buyers E; Sass AE; Severn CD; Pyle L; Cree-Green M
    J Pediatr Adolesc Gynecol; 2021 Feb; 34(1):33-39. PubMed ID: 32919086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding related to etonogestrel subdermal implant in a US population.
    Casey PM; Long ME; Marnach ML; Bury JE
    Contraception; 2011 May; 83(5):426-30. PubMed ID: 21477684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
    Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
    Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study.
    Griffin L; Hammond C; Liu D; Rademaker AW; Kiley J
    Contraception; 2017 Jun; 95(6):564-570. PubMed ID: 28238839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals.
    Kendall PD; Bresnitz W; Huang J; Sheeder J; Lazorwitz A
    Contraception; 2024 Sep; 137():110486. PubMed ID: 38754757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of age on tolerability, safety and effectiveness of subdermal contraceptive implants.
    López Del Cerro E; Serrano Diana C; Castillo Cañadas AM; González Mirasol E; García Santos F; Gómez García MT; González de Merlo G
    J Obstet Gynaecol; 2018 Oct; 38(7):979-984. PubMed ID: 29553853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.